VolitionRx 10-Q: Going-Concern Doubt Persists With $2.4M Cash and NYSE Equity Deficiency
VNRX sits 18% above its 52-week low of $0.156 on light trading volume (0.1× avg).
Summary
VolitionRx's Q3 10-Q shows $2.4 million of cash, a $17.8 million nine-month net loss and an explicit going-concern warning, alongside a NYSE American equity deficiency and heavy ATM-funded dilution.
Key Events · Earnings and Guidance · VNRX
-
Going-Concern Doubt Reaffirmed
Management concluded its plans 'do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year' from the issuance of the financial statements.
-
Cash Thin Against Burn
Cash and equivalents were $2,357,067 at September 30, 2026, against a $17.8 million nine-month net loss and $15.0 million of cash used in operations.
-
NYSE American Equity Deficiency
A February 6, 2026 notice flagged non-compliance with the $6.0 million stockholders' equity standard; the exchange accepted a plan giving until August 6, 2027 to regain compliance, with stockholders' deficit at $27.5 million.
-
Quarter Funded by ATM Sales
The company sold 10,935,126 shares under its ATM for about $5,219,393 net in Q3 and $11,842,078 over nine months, with a further 1,813,690 shares for about $342,252 sold from October 1 to November 5, 2026.
Analysis · VNRX · Life Sciences
The Q3 numbers were already out this morning via 8-K, but the full 10-Q carries the harder facts. Management explicitly concludes its cost cuts, licensing hopes and ATM sales do not remove substantial doubt about surviving the next twelve months, with only $2.4 million of cash against a $17.8 million nine-month net loss and $15.0 million of operating cash burn. Layered on top is a NYSE American listing deficiency — stockholders' equity of negative $27.5 million versus the $6.0 million minimum — with a compliance plan accepted but a deadline of August 6, 2027. The quarter was funded by issuing stock: 10.9 million ATM shares for $5.2 million in Q3 alone, plus Lind note conversions at a conversion price that has ratcheted down to $0.44. Revenue growth of 157% is real but largely a $1.5 million catch-up of deferred Heska revenue, not new cash. The equity is a survival story priced off continued dilution.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNRX was trading at $0.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.16 to $8.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.